Impact of patient nationality on the severity of early side effects after radiotherapy.
Immigration
Personalize therapy
Preventive medicine
Radiation therapy
Side effects
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
18
11
2022
accepted:
29
11
2022
medline:
23
10
2023
pubmed:
11
12
2022
entrez:
10
12
2022
Statut:
ppublish
Résumé
Major demographical changes in Germany commenced in the 1960s. Ongoing humanitarian crises in the Ukraine with subsequent immigration will have also long-range effects on national provision of cancer treatment. Ensuring the best possible outcomes for each cancer patient undergoing radiotherapy requires the prediction and prevention of unfavorable side effects. Given that recent research has primarily focused on clinical outcome indicators solely, less is known regarding sociodemographic predictors of therapeutic outcomes, such as patient nationality. Here, we investigated whether the severity of early side effects after radiotherapy are associated with patient nationality and other sociodemographic and clinical characteristics. Out of 9187 patients treated at a German university medical center between 2017 and 2021, 178 German and 178 non-German patients were selected for matched-pair analysis based on diagnostic and demographic criteria. For all 356 patients, data on side effects from follow-up care after radiotherapy were collected. Non-German patients were more likely to have severe side effects than German patients. Side effect severity was also associated with tumor entity, concomitant therapy, body mass index, and age. Foreign cancer patients are at higher risk of experiencing severe side effects of radiotherapy, suggesting a need to develop and implement targeted preventive measures for these patients. Further research investigating factors predicting the occurrence of radiotherapy side effects, including other sociodemographic characteristics, is needed to better personalize therapy regimens for cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Major demographical changes in Germany commenced in the 1960s. Ongoing humanitarian crises in the Ukraine with subsequent immigration will have also long-range effects on national provision of cancer treatment. Ensuring the best possible outcomes for each cancer patient undergoing radiotherapy requires the prediction and prevention of unfavorable side effects. Given that recent research has primarily focused on clinical outcome indicators solely, less is known regarding sociodemographic predictors of therapeutic outcomes, such as patient nationality. Here, we investigated whether the severity of early side effects after radiotherapy are associated with patient nationality and other sociodemographic and clinical characteristics.
METHODS
METHODS
Out of 9187 patients treated at a German university medical center between 2017 and 2021, 178 German and 178 non-German patients were selected for matched-pair analysis based on diagnostic and demographic criteria. For all 356 patients, data on side effects from follow-up care after radiotherapy were collected.
RESULTS
RESULTS
Non-German patients were more likely to have severe side effects than German patients. Side effect severity was also associated with tumor entity, concomitant therapy, body mass index, and age.
CONCLUSION
CONCLUSIONS
Foreign cancer patients are at higher risk of experiencing severe side effects of radiotherapy, suggesting a need to develop and implement targeted preventive measures for these patients. Further research investigating factors predicting the occurrence of radiotherapy side effects, including other sociodemographic characteristics, is needed to better personalize therapy regimens for cancer.
Identifiants
pubmed: 36495329
doi: 10.1007/s00432-022-04505-0
pii: 10.1007/s00432-022-04505-0
pmc: PMC10356627
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5573-5582Informations de copyright
© 2022. The Author(s).
Références
Crit Care Med. 2009 Jan;37(1):89-95
pubmed: 19050633
Nat Rev Dis Primers. 2019 Feb 21;5(1):13
pubmed: 30792503
Sci Transl Med. 2013 Jun 12;5(189):189sr4
pubmed: 23761042
Cancer Causes Control. 2018 Dec;29(12):1305-1309
pubmed: 30569331
Nat Rev Cancer. 2004 Sep;4(9):737-47
pubmed: 15343280
BMC Health Serv Res. 2008 Oct 07;8:207
pubmed: 18840290
Lancet Oncol. 2007 Nov;8(11):1007-17
pubmed: 17976611
Cancer Med. 2019 May;8(5):2623-2635
pubmed: 30897287
Support Care Cancer. 2011 Sep;19(9):1421-7
pubmed: 20694564
Metabolism. 2013 Jan;62 Suppl 1:S2-5
pubmed: 23021037
Soc Sci Med. 2012 Apr;74(7):1062-72
pubmed: 22326103
World J Urol. 2013 Dec;31(6):1483-8
pubmed: 23306784
BMC Cancer. 2021 May 10;21(1):526
pubmed: 33971845
Cancers (Basel). 2022 Apr 22;14(9):
pubmed: 35565227
Pharmacoeconomics. 2013 Sep;31(9):753-66
pubmed: 23963867
Soc Sci Med. 2010 Sep;71(6):1161-72
pubmed: 20624666
EPMA J. 2016 Oct 25;7:23
pubmed: 27800037
Curr Pharm Biotechnol. 2017;18(3):194-203
pubmed: 28240172
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Lancet. 2013 Apr 6;381(9873):1235-45
pubmed: 23541058
Lancet. 2015 May 23;385(9982):2118-9
pubmed: 25957453
Int J Cancer. 2012 Jul 15;131(2):E122-8
pubmed: 22052616
Med Care. 2015 Sep;53(9):e65-72
pubmed: 23703645
Nat Med. 2011 Mar;17(3):297-303
pubmed: 21383744
Int J Cancer. 2017 Apr 15;140(8):1770-1780
pubmed: 28063159
Eur J Cancer. 2010 Sep;46(14):2647-59
pubmed: 20843493
J Laryngol Otol. 2016 May;130(S2):S32-S40
pubmed: 27841109
Chin J Cancer. 2017 Mar 6;36(1):26
pubmed: 28264724
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Eur Respir J. 2017 Oct 19;50(4):
pubmed: 29051268
Oncol Res Treat. 2017;40(12):764-771
pubmed: 29183022
J Clin Oncol. 2004 Sep 1;22(17):3485-90
pubmed: 15337796
Int J Cancer. 2018 Dec 15;143(12):3097-3105
pubmed: 29987865
Med Decis Making. 2010 May-Jun;30(3):328-40
pubmed: 20086232
Mol Oncol. 2020 Jul;14(7):1538-1554
pubmed: 32521079
Int J Public Health. 2011 Oct;56(5):493-501
pubmed: 21512755
Urologe A. 2019 Oct;58(10):1179-1184
pubmed: 31338523
BMC Cancer. 2008 Nov 28;8:355
pubmed: 19040749
Nat Rev Cancer. 2007 Dec;7(12):949-60
pubmed: 18034185
BMC Cancer. 2019 Oct 30;19(1):1024
pubmed: 31666035
Cancer Manag Res. 2017 Aug 18;9:363-371
pubmed: 28860859
Health Aff (Millwood). 2018 May;37(5):694-701
pubmed: 29733705
Gesundheitswesen. 2011 May;73(5):298-307
pubmed: 20383824
Am Soc Clin Oncol Educ Book. 2015;:9-16
pubmed: 25993135
Radiologe. 2018 Aug;58(8):754-761
pubmed: 29947933
Arch Public Health. 2021 May 24;79(1):86
pubmed: 34030735
Int J Public Health. 2011 Oct;56(5):541-8
pubmed: 21038108
Int J Equity Health. 2018 Nov 1;17(1):160
pubmed: 30382861